

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hong Kong Life Sciences and Technologies Group Limited

香港生命科學技術集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8085)

PROFIT WARNING

This announcement is made by Hong Kong Life Sciences and Technologies Group Limited (the “**Company**”) and together with its subsidiaries (collectively, the “**Group**”), pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on the Growth Enterprise Market (“**GEM**”) of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and the potential investors that the consolidated annual results of the Group for the year ended 31 March 2014 (the “**Annual Results**”) may incur a significant increase in loss as compared to the last year. The loss was mainly attributable to (i) the disposal of discontinued operation in relation to the funeral and related businesses of approximately HK\$52 million as disclosed in the third quarterly report 2013/2014; and (ii) further impairment loss of goodwill for the acquisition of 159 Regenerative Medicine Group (H.K.) Limited and its subsidiaries in September 2012.

As the Company is still in the process of finalizing the Annual Results, the information contained in this announcement is only based on the preliminary assessment by the management of the Company with reference to the unaudited consolidated management accounts of the Group, which has not been confirmed by the Company’s auditor. The Annual Results will be published on 25 June 2014.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Hong Kong Life Sciences and Technologies Group Limited
Lu Zhiqiang
Executive Director and Chief Executive Officer

Hong Kong, 10 June 2014

As at the date of this announcement, the Board comprises (i) six executive Directors, namely Mr. Jiang Hongqing, Mr. David Lin Kao Kun, Mr. Lu Zhiqiang, Mr. Chu Hon Pong, Mr. Chui Kwong Kau and Mr. Cai Da; (ii) one non-executive Director, namely Ms. Lam Kuo; and (iii) four independent non-executive Directors, namely Mr. Chi Chi Hung, Kenneth, Mr. Chan Yun Hing, Mr. Gui Qiangfang and Mr. Hung Yat Ming.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the GEM website at <http://www.hkgem.com> for a minimum period of seven days from the date of its publication and on the Company’s website at <http://www.hklifesciences.com>.